Compound ID | 238
Class: Antimicrobial peptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive & Antimycobacterial |
| Mechanism of action: | Cell wall synthesis inhibitor. Lipid II inhibitor |
| Target Pathogen: | Active against Staphylococcus aureus, enterococci, Mycobacterium tuberculosis, Clostridium difficile, and Bacillus anthracis |
| Description: | Natural product from Eleftheria terrae; shows efficacy in mouse septicaemia model; a depsipeptide composed of enduracididine, methylphenylalanine, and D-amino acids |
| Institute where first reported: | Novobiotic pharmaceuticals, USA (northeastern) |
| Year first mentioned: | 2015 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/86341926 |
| Guide to Pharmacology: | teixobactin |
| Citations: |
|